Document is current
Any future updates will be listed below
-
Authors
Ma, Xingru
Marek, Robert D.
Gammell, Susannah
Summers, Amanda N.
Wang, Tao
Liu, Cong-Xiao
Lei, Gangjun
Wei, Junping
Crosby, Erika J.
Hobeika, Amy
Lyerly, H. Kim
Morse, Michael A.
Hartman, Zachary C.
-
Funding
Funding for this research was provided by:
National Institutes of Health (5T32-CA009111-45)
National Institutes of Health (1 R01CA238217-01A1/02S1)
U.S. Department of Defense (W81XWH-21-2-0031)
U.S. Department of Defense (W81XWH-20-1-0346)
Susan G. Komen (KG081026)
- License Information
-
More Information
Article History
Received: 22 October 2025
Accepted: 6 March 2026
First Online: 16 March 2026
Competing interests
: Z.C.H. and H.K.L are co-founders, and both have equity stakes in Replicate Biosciences (San Diego, CA), a srRNA platform biotech that is developing breast cancer vaccines. Z.C.H is an Associate Editor of Cancer Research Communications (CRC) and has been a guest editor at BMC Cancer and Frontiers in Immunology. None of these journals was involved in the journal’s review of, or decisions related to, this manuscript.
